CRISPR zaps HPV lesions in new trial – could it prevent cervical cancer?
NCT ID NCT07170254
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times
Summary
This early study tests a single-dose CRISPR gene therapy (BD114) in 12 women aged 25–50 with high-grade cervical lesions caused by HPV-16. The goal is to see if it safely clears the abnormal cells and the virus. While promising, this is not a cure because the virus may persist or recur, and long-term safety is still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Obstetrics & Gynecology Hospital of Fudan University
RECRUITINGShanghai, 200090, China
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.